4.5 Review

Is Aducanumab for LMICs? Promises and Challenges

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Neurosciences

Severity Distribution of Alzheimer's Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study

Jing Yuan et al.

Summary: This study characterized the severity distribution of AD dementia and MCI among prevalent cases in the Framingham Heart Study population. Results showed that half of AD dementia participants had mild disease, highlighting the need for research and interventions to slow decline or prevent progression of this burdensome disease.

JOURNAL OF ALZHEIMERS DISEASE (2021)

Article Clinical Neurology

Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study

Adam M. Brickman et al.

Summary: Blood-based Alzheimer's disease biomarkers show associations with pathological and clinical diagnoses, and have predictive value for future development of clinical AD, indicating their potential for incorporation into multi-ethnic community studies.

ALZHEIMERS & DEMENTIA (2021)

Editorial Material Medicine, General & Internal

The Problem of Aducanumab for the Treatment of Alzheimer Disease

G. Caleb Alexander et al.

ANNALS OF INTERNAL MEDICINE (2021)

Article Clinical Neurology

Can we learn lessons from the FDA's approval of aducanumab?

Kathy Y. Liu et al.

Summary: The FDA recently granted accelerated approval to aducanumab for the treatment of Alzheimer disease. Here, the authors reflect on the events that led to this controversial approval and consider whether any lessons can be learned for the field.

NATURE REVIEWS NEUROLOGY (2021)

Article Clinical Neurology

Alzheimer's disease drug development pipeline: 2021

Jeffrey Cummings et al.

Summary: Overall, the study highlights the urgent need for new treatments for Alzheimer's disease, and shows that a diverse range of drugs targeting the biology of AD are being explored in clinical trials. Biomedical biomarkers are also being increasingly used in these trials to assess effectiveness.

ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2021)

Article Clinical Neurology

Aducanumab: Appropriate Use Recommendations

J. Cummings et al.

Summary: Aducanumab has been approved for the treatment of Alzheimer's disease by the FDA. It is recommended for use in patients with early AD, with dosage titration to maximize efficacy and monitoring for amyloid-related imaging abnormalities. Patient-centered informed decision-making is emphasized for clear communication on therapy expectations, risks, and benefits.

JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2021)

Article Clinical Neurology

Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease

Samantha Budd Haeberlein et al.

Alzheimers & Dementia (2020)

Article Clinical Neurology

Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab

Lawren VandeVrede et al.

ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2020)

Article Clinical Neurology

2020 Alzheimer's disease facts and figures

[Anonymous]

ALZHEIMERS & DEMENTIA (2020)

Review Biotechnology & Applied Microbiology

Biomarkers for Alzheimer's Disease in Saliva: A Systematic Review

Helena Sophia Gleerup et al.

DISEASE MARKERS (2019)

Review Neurosciences

Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options

Jeffrey L. Cummings et al.

JOURNAL OF ALZHEIMERS DISEASE (2019)

Review Cell Biology

Alzheimer's disease: risk factors and potentially protective measures

Marcos Vinicius Ferreira Silva et al.

JOURNAL OF BIOMEDICAL SCIENCE (2019)

Review Medicine, General & Internal

Memantine for dementia

Rupert McShane et al.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2019)

Review Geriatrics & Gerontology

The Early Events That Initiate β-Amyloid Aggregation in Alzheimer's Disease

Xingyu Zhang et al.

FRONTIERS IN AGING NEUROSCIENCE (2018)

Review Medicine, General & Internal

Donepezil for dementia due to Alzheimer's disease

Jacqueline S. Birks et al.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)

Review Pharmacology & Pharmacy

The present and future of pharmacotherapy of Alzheimer's disease: A comprehensive review

Abhinav Anand et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2017)

Review Neurosciences

Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis

Taro Kishi et al.

JOURNAL OF ALZHEIMERS DISEASE (2017)

Review Medicine, Research & Experimental

Microglia in Alzheimer's disease

Heela Sarlus et al.

JOURNAL OF CLINICAL INVESTIGATION (2017)

Article Clinical Neurology

Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers

Jennifer C. Howell et al.

ALZHEIMERS RESEARCH & THERAPY (2017)

Review Clinical Neurology

Best practice in the management of behavioural and psychological symptoms of dementia

Olivier Pierre Tible et al.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2017)

Article Clinical Neurology

The worldwide costs of dementia 2015 and comparisons with 2010

Anders Wimo et al.

ALZHEIMERS & DEMENTIA (2017)

Review Cell Biology

Drug candidates in clinical trials for Alzheimer's disease

Shih-Ya Hung et al.

JOURNAL OF BIOMEDICAL SCIENCE (2017)

Review Medicine, Research & Experimental

The amyloid hypothesis of Alzheimer's disease at 25years

Dennis J. Selkoe et al.

EMBO MOLECULAR MEDICINE (2016)

Article Multidisciplinary Sciences

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

Jeff Sevigny et al.

NATURE (2016)

Letter Public, Environmental & Occupational Health

THE DISTRIBUTION OF APOLIPOPROTEIN E GENOTYPE OVER THE ADULT LIFESPAN AND IN RELATION TO COUNTRY OF BIRTH

Silke Kern et al.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2015)

Article Medicine, General & Internal

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis

Willemijn J. Jansen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)

Article Neurosciences

Oxidative stress and lipid peroxidation are upstream of amyloid pathology

Muriel Arimon et al.

NEUROBIOLOGY OF DISEASE (2015)

Review Health Care Sciences & Services

Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries

Tuan Anh Nguyen et al.

HEALTH POLICY AND PLANNING (2015)

Review Clinical Neurology

Activation of mTOR: a culprit of Alzheimer's disease?

Zhiyou Cai et al.

NEUROPSYCHIATRIC DISEASE AND TREATMENT (2015)

Article Medicine, General & Internal

Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease

Robert Howard et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Clinical Neurology

Alzheimer’s Disease: A Clinical Practice-Oriented Review

Luísa Alves et al.

Frontiers in Neurology (2012)

Article Clinical Neurology

Behavioral and Psychological Symptoms of Dementia

J. Cerejeira et al.

Frontiers in Neurology (2012)

Review Medicine, General & Internal

Cholinesterase inhibitors for Alzheimer's disease

J Birks

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2006)